Peer-Reviewed Publication
NPJ Parkinsons Dis2024;10(1):235.December 20, 2024Letter
Biologically defined neuronal synuclein disease as a tool to advance drug development.
Gennaro Pagano1,2, Tien Dam3, Geoffrey A Kerchner4, Wendy R Galpern5, Milton Biagioni6, Rajesh Karan7, Danna Jennings8, M Judith Peterschmitt9, Tania Nikolcheva10, Patrik Brundin4
1Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland. gennaro.pagano@roche.com.
2University of Exeter Medical School, London, UK. gennaro.pagano@roche.com.
3Neumora Therapeutics, Watertown, MA, USA.
4Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
5Janssen Research & Development, LLC, Cambridge, MA, USA.
6UCB Pharma, Brussels, Belgium.
7Global Drug Development, Novartis Pharma AG, Basel, Switzerland.
8Denali Therapeutics Inc., South San Francisco, CA, USA.
9Sanofi, Clinical Development Neurology, Cambridge, MA, USA.
10Product Development Neurology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Abstract
In a recent Viewpoint article (JAMA Neurol. 2024;81:789‒90), Okubadejo et al. raised concerns regarding two recent proposals for biological definitions and staging systems for synucleinopathies (the Neuronal Synuclein Disease Integrated Staging System and SynNeurGe system). While acknowledging these concerns, we provide an alternative perspective—that such frameworks represent important steps forw…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans